4.6 Article

Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study

期刊

MAYO CLINIC PROCEEDINGS
卷 96, 期 8, 页码 2114-2122

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2020.12.038

关键词

-

资金

  1. National Insti-tutes of Health [5T32DK007357, 2K24DK085446]

向作者/读者索取更多资源

The study assessed present ACEI and ARB use among patients with proteinuric CKD and found that less than half of patients had active prescriptions on the index date. Barriers such as past AKI, hyperkalemia, advanced CKD, and lack of nephrology care were associated with lower use of ACEIs/ARBs. These barriers may be inappropriate or modifiable in many cases.
Objective: To assess present angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) use among patients with proteinuric chronic kidney disease (CKD) and examine barriers limiting this guideline-concordant care. Patients and Methods: Using a nationwide database containing patient-level claims and integrated clinical information, we examined current ACEI/ARB prescriptions on the index date (April 15, 2017) and prior ACEI/ARB use in 41,743 insured adults with proteinuric CKD. Using multivariable logistic regression, we estimated adjusted associations between current ACEI/ARB use and putative barriers including past acute kidney injury (AKI), hyperkalemia, advanced CKD, and lack of nephrology care. Results: Only 49% (n=20,641) of patients had an active ACEI/ARB prescription on the index date, but 87% (n=36,199) had been previously prescribed an ACEI/ARB. Use was lower in patients with past AKI, hyperkalemia, CKD stages 4 or 5, and a lack of nephrology care (adjusted odds ratios were 0.61 [95% CI, 0.58 to 0.64], 0.76 [95% CI, 0.72 to 0.80], 0.48 [95% CI, 0.45 to 0.51], and 0.85 [95% CI, 0.81 to 0.89], respectively). Conclusion: Discontinuing, rather than never initiating, ACEI/ARB treatment limits guidelineconcordant care in proteinuric CKD. Past AKI, hyperkalemia, advanced CKD, and lack of nephrology care were associated with lower use of ACEIs/ARBs, but these putative barriers may in many instances be inappropriate (AKI and advanced CKD) or modifiable (hyperkalemia and lack of nephrology care). (c) 2021 Mayo Foundation for Medical Education and Research center dot Mayo Clin Proc. 2021;96(8):2114-2122

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据